KR20160127754A - Btk 억제제 및 akt 억제제를 포함하는 조합물 - Google Patents

Btk 억제제 및 akt 억제제를 포함하는 조합물 Download PDF

Info

Publication number
KR20160127754A
KR20160127754A KR1020167024720A KR20167024720A KR20160127754A KR 20160127754 A KR20160127754 A KR 20160127754A KR 1020167024720 A KR1020167024720 A KR 1020167024720A KR 20167024720 A KR20167024720 A KR 20167024720A KR 20160127754 A KR20160127754 A KR 20160127754A
Authority
KR
South Korea
Prior art keywords
compound
cancer
administered
combination
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167024720A
Other languages
English (en)
Korean (ko)
Inventor
라케시 쿠마
킴벌리 에이. 로벨
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20160127754A publication Critical patent/KR20160127754A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167024720A 2014-03-12 2015-02-24 Btk 억제제 및 akt 억제제를 포함하는 조합물 Withdrawn KR20160127754A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461951640P 2014-03-12 2014-03-12
US61/951,640 2014-03-12
PCT/IB2015/051380 WO2015136398A1 (en) 2014-03-12 2015-02-24 Combination comprising a btk inhibitor and an akt inhibitor

Publications (1)

Publication Number Publication Date
KR20160127754A true KR20160127754A (ko) 2016-11-04

Family

ID=52630445

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167024720A Withdrawn KR20160127754A (ko) 2014-03-12 2015-02-24 Btk 억제제 및 akt 억제제를 포함하는 조합물

Country Status (10)

Country Link
US (2) US20170020878A1 (cg-RX-API-DMAC7.html)
EP (1) EP3116546A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017507963A (cg-RX-API-DMAC7.html)
KR (1) KR20160127754A (cg-RX-API-DMAC7.html)
CN (1) CN106456642A (cg-RX-API-DMAC7.html)
AU (1) AU2015228475B9 (cg-RX-API-DMAC7.html)
CA (1) CA2942204A1 (cg-RX-API-DMAC7.html)
MX (1) MX2016011674A (cg-RX-API-DMAC7.html)
RU (1) RU2016139697A (cg-RX-API-DMAC7.html)
WO (1) WO2015136398A1 (cg-RX-API-DMAC7.html)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
NZ594064A (en) * 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
ES2590491T3 (es) 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
US9073947B2 (en) 2011-06-10 2015-07-07 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
WO2013010869A1 (en) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ, インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
CA2852964A1 (en) 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag Bicyclic piperazine compounds
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
WO2013161848A1 (ja) 2012-04-27 2013-10-31 カルナバイオサイエンス株式会社 新規1,2,4-トリアジン誘導体
MA37711A1 (fr) * 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
CN104487441B (zh) 2012-06-18 2018-06-01 普林斯匹亚生物制药公司 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶

Also Published As

Publication number Publication date
US20170020878A1 (en) 2017-01-26
CN106456642A (zh) 2017-02-22
WO2015136398A1 (en) 2015-09-17
JP2017507963A (ja) 2017-03-23
AU2015228475B2 (en) 2017-08-17
AU2015228475A1 (en) 2016-09-01
US20190151319A1 (en) 2019-05-23
RU2016139697A (ru) 2018-04-12
RU2016139697A3 (cg-RX-API-DMAC7.html) 2018-10-19
AU2015228475B9 (en) 2017-09-21
CA2942204A1 (en) 2015-09-17
EP3116546A1 (en) 2017-01-18
MX2016011674A (es) 2017-04-27

Similar Documents

Publication Publication Date Title
KR101797415B1 (ko) 암의 치료를 위한 아푸레세르팁과 조합된 엔잘루타미드
JP7235807B2 (ja) 組合せ物
MX2011008073A (es) Hidrocloruro de n-{(1-s)-2-amino -1-[(3-fluorofenil)metil]etil}-5- cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino.
AU2015228475B2 (en) Combination comprising a BTK inhibitor and an AKT inhibitor
KR20150103735A (ko) 조합물
HK40038736A (en) Combination
HK40012995A (en) Combinations for treating cancer and use thereof
HK40007974A (en) Combination

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160907

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination